Diagnostic Utility of the Immunohistochemical Expression of Serin and Arginine Rich Splicing Factor 1 (SRSF1) in the Differential Diagnosis of Adult Gliomas

Cancers

Elia Guadagno¹  Daniela Russo¹  Giuseppe Musumeci²  Grazia Maugeri²  Velia D’Agata²  Marco Ragusa³  Davide Barbagallo³  Elena Tirrò⁴  Michele Massimino⁴  Paolo Vigneri⁴  Rosario Caltabiano⁵  Giuseppe Broggi⁵  Lucia Salvatorelli⁵  Francesco Certo⁶  Roberto Altieri⁶  GiuseppeMaria Vincenzo Barbagallo⁶ 

[1] Department of Advanced Biomedical Sciences, Pathology Section, University of Naples Federico II, 80131 Naples, Italy;Department of Biomedical and Biotechnological Sciences, Section of Anatomy, Histology and Movement Sciences, University of Catania, 95123 Catania, Italy;Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics Giovanni Sichel, University of Catania, 95123 Catania, Italy;Department of Clinical and Experimental Medicine, Center of Experimental Oncology and Hematology, Policlinico “G. Rodolico-San Marco” University Hospital, University of Catania, 95123 Catania, Italy;Department of Medical and Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, Anatomic Pathology, University of Catania, 95123 Catania, Italy;Department of Medical and Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, Neurological Surgery, Policlinico “G. Rodolico-San Marco” University Hospital, University of Catania, 95123 Catania, Italy;

关键词: SRSF1;    diagnosis;    glioma;    neuropathology;    immunohistochemistry;   

DOI  :  10.3390/cancers13092086

来源: DOAJ

【 摘 要 】

Background: The aim of this study was to investigate the immunohistochemical expression and distribution of serine and arginine rich splicing factor 1 (SRSF1) in a series of 102 cases of both diffuse and circumscribed adult gliomas to establish the potential diagnostic role of this protein in the differential diagnosis of brain tumors. Methods: This retrospective immunohistochemical study included 42 glioblastoma cases, 21 oligodendrogliomas, 15 ependymomas, 15 pilocytic astrocytomas, 5 sub-ependymal giant cell astrocytoma and 4 pleomorphic xanthoastrocytomas. Results: Most glioblastoma (81%), oligodendroglioma (71%), sub-ependymal giant cell astrocytoma (80%) and pleomorphic xanthoastrocytoma (75%) cases showed strong SRSF1 immunoexpression, while no detectable staining was found in the majority of ependymomas (87% of cases) and pilocytic astrocytomas (67% of cases). Conclusions: The immunohistochemical expression of SRSF1 may be a promising diagnostic marker of astrocytomas and oligodendrogliomas and its increased expression might allow for excluding entities that often enter into differential diagnosis, such as ependymomas and pilocytic astrocytomas.

【 授权许可】

Unknown